Background. Survival after liver resection for HCC is compromised by a high rate of intrahepatic recurrence. Adjuvant treatment\nwith a single, postoperative dose of intra-arterial I131 lipiodol has shown promise, as a means of prolonging disease-free survival\n(DFS).Methodology.DFS and overall survival (OS) after a single dose of postoperative I131 lipiodol were compared to liver resection\nalone, for treatment of hepatocellular carcinoma (HCC). Data were collected retrospectively for patients who had a curative\nresection for HCC between December 1993 and September 2011. Seventy-two patients were given I131 lipiodol after surgery and\n70 patients had surgery alone. Results.The DFS at 1, 3, and 5 years was 72%, 43%, and 26% in the surgery group and 70%, 39%, and\n29% in the adjuvant I131 lipiodol group (
Loading....